Manila Times Business
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that on June 1, 2026, the Company granted restricted stock units (RSUs) representing 67,300 shares of its common stock to two newly-hired non-executive employees. The grants were
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Keystone Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering
2h ago
Moderna Launches Moderna Direct with "eCommerce Powered by FFF Enterprises™”
2h ago
ATN International, Inc. Completes Initial Closing on the Sale of its Towers and Updates 2026 Outlook
2h ago
Neuronetics Appoints Robert Greene as Senior Vice President Sales
2h ago